Your browser doesn't support javascript.
loading
In vitro release test (IVRT): Principles and applications.
Shah, Vinod P; Simona Miron, Dalia; Ștefan Radulescu, Flavian; Cardot, Jean-Michel; Maibach, Howard I.
Afiliación
  • Shah VP; Pharmaceutical Consultant, 11309 Dunleith Place, North Potomac, MD 20878, USA. Electronic address: dr.vpshah@comcast.net.
  • Simona Miron D; Center for Drug Sciences, Faculty of Pharmacy, University of Medicine and Pharmacy Carol Davila Bucharest, 6 Traian Vuia, 020956 Bucharest, Romania. Electronic address: dalia.miron@umfcd.ro.
  • Ștefan Radulescu F; Center for Drug Sciences, Faculty of Pharmacy, University of Medicine and Pharmacy Carol Davila Bucharest, 6 Traian Vuia, 020956 Bucharest, Romania. Electronic address: flavian.radulescu@umfcd.ro.
  • Cardot JM; SAS Borvo, 18 avenue de Charade, 63122 Ceyrat, France. Electronic address: jean-michel.cardot@wanadoo.fr.
  • Maibach HI; Department of Dermatology, School of Medicine, University of California, 2340 Sutter Street N461, 94115 San Francisco, CA, United States of America. Electronic address: Howard.Maibach@ucsf.edu.
Int J Pharm ; 626: 122159, 2022 Oct 15.
Article en En | MEDLINE | ID: mdl-36067919
ABSTRACT
In vitro drug release test has become one of the most important tools for drug development and approval process of semisolid dosage forms. In vitro release test (IVRT) has the ability to reflect the combined effects of several physicochemical characteristics, particle or droplet size, viscosity, microstructure arrangement of the matter and state of aggregation of dosage form. Genesis of IVRT, its principles and rank order relationship with pharmacodynamic response such as vasoconstriction or dermatopharmacokinetic (skin stripping) results and the evolution of test requirements for regulatory approval is discussed. IVRT reflects various parameters and is an essential part of the stepwise approach to compare topical formulation and its ability to release active in similar quantity at similar rate. Therefore, it is an essential tool, in addition to similar qualitative and quantitative composition (Q1 Q2), to assess the similarity of microstructural arrangement (Q3) as proposed in the Topical drug Classification System (TCS) approach of classes 1 and 3. The TCS system along with evolving concept for topical dermatological drug products from Q1, Q2, Q3 sameness to Q1, Q2, Q3 similar allowing greater permissiveness in formulation changes is discussed.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Liberación de Fármacos Tipo de estudio: Qualitative_research Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Liberación de Fármacos Tipo de estudio: Qualitative_research Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article